医院适配吸入噬菌体治疗耐多药肺炎克雷伯菌所致呼吸机相关性肺炎:一项比较性先导研究
这项前瞻性、单中心、开放标签、非随机干预性先导研究,纳入耐多药肺炎克雷伯菌呼吸机相关性肺炎患者,每组7例,分为针对性噬菌体组、非针对性噬菌体对照组和单用抗生素对照组,所有患者均接受标准抗生素治疗。噬菌体经雾化吸入,每日两次,疗程14天。主要终点为第14天呼吸道标本中肺炎克雷伯菌微生物学清除,针对性噬菌体组为86%(6/7),单用抗生素组为57%(4/7),非针对性噬菌体组为0%(0/7)。针对性噬菌体组组内氧合有显著改善(p=0.0247),并更早降阶梯呼吸支持及停用抗生素,吸入噬菌体耐受良好,无治疗相关不良事件。
要点
- 针对性吸入噬菌体组第14天肺炎克雷伯菌清除率86%(6/7),单用抗生素组57%(4/7),非针对性噬菌体组0%(0/7)。
- 针对性噬菌体组组内氧合显著改善(p=0.0247),并更早降阶梯呼吸支持及停用抗生素。
- 吸入噬菌体给药耐受良好,未报告治疗相关不良事件。
- 三组生命体征及实验室指标无显著组间差异。
- 合并其他院内病原体定植(主要为鲍曼不动杆菌和粘质沙雷菌)常见,但未显示对肺炎克雷伯菌清除的竞争性干扰。
适用人群与场景
- 耐多药肺炎克雷伯菌所致呼吸机相关性肺炎的危重症患者,所有患者均接受标准抗生素治疗。
处置流程与药物剂量
- 噬菌体鸡尾酒基于当地分离株的回顾性基因组和表型分析设计,经雾化吸入给药,每日两次,疗程14天。
- 所有患者均接受标准抗生素治疗。
研究设计与关键结果
- 前瞻性、单中心、开放标签、非随机干预性先导研究,每组7例,共三组:针对性噬菌体组、非针对性噬菌体对照组和单用抗生素对照组。
- 主要终点第14天呼吸道标本肺炎克雷伯菌微生物学清除率:针对性噬菌体组86%(6/7),单用抗生素组57%(4/7),非针对性噬菌体组0%(0/7)。
- 针对性噬菌体组组内氧合显著改善(p=0.0247),并更早降阶梯呼吸支持及停用抗生素。
- 三组生命体征及实验室指标无显著组间差异;吸入噬菌体耐受良好,无治疗相关不良事件。
- 合并其他院内病原体定植(主要为鲍曼不动杆菌和粘质沙雷菌)常见,但未显示对肺炎克雷伯菌清除的竞争性干扰。
证据类型、等级与局限
- 证据类型:前瞻性、单中心、开放标签、非随机干预性先导研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这种从当地肺炎克雷伯菌流行病学出发的转化方法可被评估纳入重症监护病房工作流程,将医院适配噬菌体鸡尾酒定位为广谱噬菌体治疗与个体化噬菌体治疗之间的潜在中间选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant Klebsiella pneumoniae (MDR-Kp) remains a major clinical challenge in critically ill patients. While bacteriophage therapy shows promise, clinical data on inhaled formulations are limited.
METHODS: In this prospective, single-center, open-label, non-randomized interventional pilot study, we evaluated the efficacy and safety of a hospital-adapted phage cocktail in patients with MDR-Kp VAP. The cocktail was designed based on retrospective genomic and phenotypic analysis of local isolates. All patients received standard antibiotics and were assigned to three groups (n = 7 each): targeted phage therapy (cocktail active in vitro), non-targeted phage control (cocktail inactive in vitro), or control (no phage). A non-target phage control group was included to evaluate possible non-specific or immunomodulatory effects of phage presence in the respiratory tract. Phages were administered via nebulization twice daily for 14 days. The primary endpoint was microbiological eradication of any K. pneumoniae at day 14; secondary endpoints included clinical response and safety, assessed through clinical and laboratory parameters.
RESULTS: By day 14, microbiological eradication of K. pneumoniae from respiratory samples was documented in 86% (6/7) of patients receiving targeted phage therapy, compared to 57% (4/7) with antibiotics alone and 0% (0/7) with non-targeted phages. Distinct patterns of infection dynamics were observed, with targeted therapy associated with more rapid and consistent clearance. Co-colonization with other nosocomial pathogens (primarily A. baumannii and S. marcescens) was common but showed no evidence of competitive interference with K. pneumoniae eradication. No significant between-group differences were observed in vital signs or laboratory indices; however, the PT group exhibited a significant within-group improvement in oxygenation (p = 0.0247), alongside earlier de-escalation of ventilatory support and discontinuation of antibiotics. Inhaled phage administration was well tolerated, with no therapy-related adverse events.
CONCLUSIONS: This comparative pilot study outlines a translational approach from local K. pneumoniae epidemiology to hospital-adapted phage cocktails. Although preliminary, our findings illustrate how this pragmatic approach could be evaluated into intensive care unit workflows, positioning hospital-adapted cocktails as a potential middle ground between broad-spectrum and personalized phage therapy.
参考来源
- Gorodnichev R, Shitikov E, Gurkova M, et al. Hospital-adapted inhaled phage therapy for ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae: a comparative pilot study. Crit Care. 2026. PMID: 41530788. doi:10.1186/s13054-026-05839-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。